Skip to main content

Viatris Inc Japan, Australia and New Zealand Segment revenue

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

Japan, Australia and New Zealand Segment revenue at Viatris Inc came to $291.0M for the quarter to 30 Sep 2026, down 5.3% from a year earlier.

As Viatris Inc reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.

By quarter

$372.3MDec 2023$318.1MMar 2024$349.8MJun 2024$345.5MSep 2024$336.3MDec 2024$277.1MMar 2025$306.7MJun 2025$307.3MSep 2025$306.6MDec 2025$273.5MMar 2026$296.2MJun 2026$291.0MSep 2026
Viatris Inc Japan, Australia and New Zealand Segment revenue, every reported period
Period endingJapan, Australia and New Zealand Segment revenueChange on a yearFiled
30 Sep 2026$291.0Mdown 5.3%5 Nov 2026
30 Jun 2026$296.2Mdown 3.4%6 Aug 2026
31 Mar 2026$273.5Mdown 1.3%7 May 2026
31 Dec 2025$306.6Mdown 8.8%26 Feb 2026
30 Sep 2025$307.3Mdown 11.1%6 Nov 2025
30 Jun 2025$306.7Mdown 12.3%7 Aug 2025
31 Mar 2025$277.1Mdown 12.9%8 May 2025
31 Dec 2024$336.3Mdown 9.7%27 Feb 2025
30 Sep 2024$345.5Mup 3.3%7 Nov 2024
30 Jun 2024$349.8Mdown 6.8%8 Aug 2024
31 Mar 2024$318.1Mdown 7.0%9 May 2024
31 Dec 2023$372.3Mdown 6.6%28 Feb 2024
30 Sep 2023$334.5Mdown 12.7%8 Nov 2023
30 Jun 2023$375.5Mdown 12.1%7 Aug 2023
31 Mar 2023$342.2Mdown 19.3%8 May 2023
31 Dec 2022$398.5Mdown 26.1%27 Feb 2023
30 Sep 2022$383.0Mdown 24.2%7 Nov 2022
30 Jun 2022$427.1Mdown 14.8%8 Aug 2022
31 Mar 2022$423.8Mdown 12.1%9 May 2022
31 Dec 2021$539.2Mup 38.4%28 Feb 2022
30 Sep 2021$505.3Mup 78.9%8 Nov 2021
30 Jun 2021$501.0Mup 78.8%9 Aug 2021
31 Mar 2021$481.9Mup 98.1%10 May 2021
31 Dec 2020$389.5M—1 Mar 2021
30 Sep 2020$282.4M—10 Nov 2020
30 Jun 2020$280.2M—12 Aug 2020
31 Mar 2020$243.2M—12 May 2020

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Viatris Inc: Brands revenue · Generics revenue · Lipitor revenue · Norvasc revenue · EpiPen® Auto-Injectors revenue · Lyrica ® revenue · Creon ® revenue · Viagra ® revenue · Influvac ® revenue · Zoloft ® revenue · Yupelri ® revenue · Celebrex ® revenue · Effexor ® revenue · Xalabrands revenue · Xanax ® revenue · Amitiza ® revenue · Dymista ® revenue · Developed Markets Segment revenue · Greater China revenue · Emerging Markets Segment revenue · financial statements

Every KPI and segment of VTRS, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.